Get the Daily Brief
Latest Biotech News
Genmab Moves to Acquire Merus for $8 Billion to Expand Cancer Pipeline
Danish biotech Genmab announced plans to acquire Dutch company Merus in an $8 billion all-cash deal. The acquisition brings Merus’s promising head and neck cancer bispecific antibody,...
MoonLake’s Stock Collapses After Mixed Results in Hidradenitis Suppurativa Trials
MoonLake Immunotherapeutics suffered a significant market value loss after its sole pipeline drug failed to meet primary endpoints in pivotal Phase 3 trials targeting hidradenitis suppurativa, an...
Sanofi Expands Venture Capital Funding with $625 Million Injection
Pharmaceutical giant Sanofi plans to augment its corporate venture arm, Sanofi Ventures, with a $625 million capital infusion, increasing assets under management to over $1.4 billion. The...
AI Enhances Real-Time Glioblastoma Diagnosis During Surgery
A team led by Harvard Medical School unveiled an AI-based tool capable of distinguishing glioblastoma from visually similar brain tumors intraoperatively with high accuracy. This advancement...
Breakthrough Biomarker Predicts Anti-CD20 Therapy Response in Multiple Sclerosis
Researchers have identified serum CST5 as a predictive marker of resistance to anti-CD20 antibody therapy in multiple sclerosis (MS) patients. Proteomic profiling of patient sera suggests CST5...
Simcere Zaiming Secures FDA IND for CDH17-Targeting Antibody-Drug Conjugate
Simcere Zaiming Pharmaceutical has achieved Investigational New Drug (IND) clearance from the FDA for SIM-0609, a novel CDH17-directed antibody-drug conjugate designed to treat advanced solid...
Novel Lectin-Based Therapeutics Target Tumor-Associated Carbohydrates Across Cancer Types
Researchers at University of California, Irvine, engineered lectin proteins that bind tumor-associated carbohydrate antigens with high affinity resembling a velcro mechanism. These lectin-based...
Groundbreaking Low-Dose Radiation Provides Relief for Knee Osteoarthritis Pain
A randomized placebo-controlled trial from South Korea demonstrated significant pain reduction in mild-to-moderate knee osteoarthritis patients following low-dose radiation therapy. This novel...
Thyme Care Raises $97 Million to Accelerate Value-Based Cancer Care Models
Thyme Care closed a $97 million Series D funding round, featuring participation from CVS Health Ventures, Foresite Capital, Morgan Health, and Humana, bringing total equity raised to $275 million....
uniQure’s Gene Therapy Yields Major Huntington’s Disease Breakthrough – Shares Surge Fivefold
uniQure announced compelling 36-month data from its Phase I/II trial of AMT-130 gene therapy for Huntington’s disease, demonstrating a 75% slowing of disease progression on the composite Unified...
Genmab Pays $8 Billion to Acquire Merus’ Bispecific Cancer Drug Pipeline
Danish biotech Genmab revealed plans to acquire Dutch company Merus in an $8 billion cash deal, representing a 41% premium on Merus’s stock price. Merus’s lead asset is petosemtamab, a bispecific...
Sanofi Ventures Elevates Investment with $625 Million Injection to Spur Early-Stage Innovation
Sanofi Ventures has announced a substantial $625 million capital raise, bringing its total assets under management to approximately $1.4 billion. This infusion is targeted at accelerating...
Thyme Care Secures $97 Million to Advance Value-Based Cancer Care Models
Thyme Care completed a $97 million Series D funding led by CVS Health Ventures and prominent investors including Foresite Capital, Morgan Health, and Humana. The company has raised $275 million to...
New AI Tool Enables Real-Time Differentiation of Glioblastoma During Surgery
A Harvard Medical School-led team developed an artificial intelligence–powered diagnostic tool capable of distinguishing glioblastoma multiforme from visually similar brain tumors intraoperatively...
Combination Radiopharmaceutical and Stereotactic Radiation Shows Promise in Oligometastatic Prostate Cancer
The Phase II LUNAR trial demonstrated that adding a PSMA-targeted radiopharmaceutical to stereotactic body radiation therapy (SBRT) significantly slowed progression in oligometastatic prostate...
Cochrane Review Confirms Safety and Efficacy of Respiratory Syncytial Virus Vaccines
A comprehensive systematic review published in the Cochrane Database analyzed 14 randomized clinical trials with over 100,000 participants, conclusively demonstrating that RSV vaccines have robust...
Tirzepatide Demonstrates Dual Weight Management Benefits for Patients With and Without Diabetes
An international meta-analysis detailed the efficacy and safety profile of tirzepatide—a dual GIP and GLP-1 receptor agonist—unveiling its marked benefits for weight loss across multiple...
Engineering Macrophages Offers New Horizons in Precision Melanoma Therapy
A study in the Journal of Translational Medicine led by Liu et al. presented cutting-edge research on genetically engineered macrophages that augment immunotherapy efficacy against melanoma. These...
Uniquely Designed Living Robots Made from Lung Cells Aim to Deliver Targeted Treatments
Carnegie Mellon University researchers unveiled AggreBots, microscopic living robots constructed from human lung cells with customizable motility enabled by a novel tissue engineering platform....
Genmab to Acquire Merus for $8 Billion in Oncology Push
Danish biotech company Genmab has announced plans to acquire Dutch firm Merus in an $8 billion cash deal, representing a 41% premium over Merus's recent closing share price. Merus is advancing...